Medication guide

Saxenda is leaving the US market, with last shipments to wholesalers in late January 2027

Novo Nordisk is discontinuing Saxenda (liraglutide) in the US. Its notice says the last shipments to wholesalers take place in late January 2027, and that the decision is not about safety or quality. Generic liraglutide, the Wegovy pill and pen, and Foundayo remain available, at the cash prices below.

Eduard Cristea
Eduard Cristea
Published:
An unbranded injection pen beside a desk calendar and a glass of water

What changed, with dates

  • Late January 2027: last Saxenda shipments to US wholesalers, per Novo Nordisk's notice to clinicians and NovoCare (both read November 20, 2026).
  • Why: Novo says patient numbers kept falling as more FDA-approved options arrived, and calls it a strategic portfolio decision, not a safety or quality issue.
  • Savings card: already gone. It closed to new enrollees on June 30, 2023 and its benefits ended on December 31, 2023.
  • Generic: Teva announced FDA approval and US launch of a generic of Saxenda on August 28, 2025 (report).
  • Help line: Novo Nordisk Customer Care Center, 1-800-727-6500.

What the FDA-approved alternatives cost today

Cash prices from each maker's own page, read November 20, 2026 unless the row says otherwise. Your prescriber picks the drug and strength.

DrugSelf-pay priceSource
Wegovy pill (semaglutide)$149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) a monthNovo Nordisk
Wegovy pen (semaglutide)$199 a month for a new patient's first 2 fills of 0.25 mg or 0.5 mg through Dec 31, 2026, then $349; Wegovy HD 7.2 mg $399Novo Nordisk
Foundayo pill (orforglipron)From $149 (0.8 mg and 2.5 mg), $199 (5.5 mg), $299 (9 mg and up) a month at LillyDirectEli Lilly
Zepbound KwikPen (tirzepatide)From $299 a month at the starting strength, up to $449 at higher dosesEli Lillyread Nov 6, 2026

With commercial coverage, the Wegovy and Foundayo savings offers can bring the cost to as little as $25 a month. Eligible Medicare Part D members can pay $50 a month for Wegovy, Foundayo or Zepbound KwikPen through the Medicare GLP-1 Bridge. More detail: Wegovy pill cost, Foundayo guide, Foundayo vs Wegovy pill.

How to switch from Saxenda: what the FDA labels say

No FDA label gives a dose conversion from Saxenda. Each new drug begins at the starting dose its own label sets, then steps up on that label's schedule, so your full Saxenda dose does not carry over. The table quotes each label's starting instruction word for word, from DailyMed, read November 20, 2026. Your prescriber decides which drug you move to, where you start and how fast you step up.

DrugFormThe label's starting instruction
Wegovy pen (semaglutide)Weekly injection“Initiate at 0.25 mg once weekly for 4 weeks.” FDA label
Wegovy pill (semaglutide)Daily tablet“Initiate WEGOVY tablet with a dosage of 1.5 mg once daily for 30 days.” FDA label
Zepbound (tirzepatide)Weekly injection“The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks.” FDA label
Foundayo (orforglipron)Daily tablet“Starting dosage is 0.8 mg once daily. After at least 30 days, increase dosage to 2.5 mg once daily.” FDA label
Saxenda (liraglutide), for referenceDaily injection“Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached.” FDA label
  • No overlap: each of these labels says using the drug with another GLP-1 receptor agonist is not recommended (Saxenda, Wegovy, Zepbound, Foundayo). The switch is a stop and a start; your prescriber sets both dates.
  • Same drug, new maker: generic liraglutide keeps your daily shot and the Saxenda label's schedule. Ask your pharmacy what it stocks.
  • Pills: the Wegovy pill and Foundayo are daily tablets, priced from $149 a month at the lowest strength in the table above.
  • Compounded: compounded semaglutide and tirzepatide cost less, but the FDA says compounded drugs are not FDA-approved and it does not review them for safety, effectiveness or quality before they are marketed.
  • Insurance: a new drug usually needs a new prior authorization. Ask your plan before your last Saxenda fill.

Before your last pen: a checklist

  1. Call your pharmacy: how much Saxenda does it hold, and does it stock generic liraglutide?
  2. Book your prescriber now. Bring your current dose, how long you have taken it, your results and any side effects.
  3. Ask your plan which GLP-1 drugs it prefers and what its prior authorization needs.
  4. Price both routes: your insured cost against the cash prices above.
  5. Get the stop and start dates in writing, so you never take two GLP-1 drugs at once.

Your options now: telehealth programs

Programs in our published order, with the price on our record. Compounded medications are not FDA-approved and are not the brand products.

  • Embody

    from $49/mo on a 12-month plan; $79/mo semaglutide, $129/mo tirzepatide, monthly plan

    Check price at Embody
  • TrimRx

    From $179 (seller says GLP-1), from $279 (seller says GLP-1 + GIP), plan term not stated

    Check price at TrimRx
  • SnagRx

    $59/mo semaglutide, $109/mo tirzepatide, sale price, plan term not stated

    Check price at SnagRx

Every recorded program: the full directory.

FAQ

Is Saxenda being discontinued?
Yes, in the US. Novo Nordisk's notice says it is discontinuing Saxenda, with last shipments to wholesalers in late January 2027 (read November 20, 2026).
Why is Saxenda being discontinued?
Novo Nordisk gives two reasons: fewer patients use Saxenda as more FDA-approved options have become available, and a strategic portfolio decision. It says the decision is not the result of any safety or quality concern.
Can I still fill my Saxenda prescription?
Pharmacies can fill it while stock lasts. The last shipments to wholesalers are planned for late January 2027, so supply after that depends on what your pharmacy holds. Talk to your prescriber about a switch before you run short.
Is there a generic Saxenda?
Yes. Teva announced FDA approval and the US launch of a generic of Saxenda (liraglutide injection) on August 28, 2025. Ask your pharmacy which liraglutide it stocks and its cash price.
Is there still a Saxenda savings card?
No. Novo Nordisk's page says the Saxenda savings offer closed to new enrollees on June 30, 2023, and its benefits ended on December 31, 2023.
What can I switch to from Saxenda?
Your prescriber decides. The FDA-approved options with published cash prices include the Wegovy pill (from $149 a month), the Wegovy pen ($199 a month for a new patient's first two fills through December 31, 2026, then $349) and Foundayo (from $149 a month). Prices read November 20, 2026.
What is the Saxenda to Wegovy dose conversion?
There is none in the FDA labels. Saxenda (liraglutide) and Wegovy (semaglutide) are different drugs, and the Wegovy label starts every new patient at its own starting dose, then steps up on its own schedule. The same is true of Zepbound and Foundayo. Your prescriber decides where you start (labels read November 20, 2026).
Can I take Saxenda and Wegovy together?
No. The Saxenda, Wegovy, Zepbound and Foundayo labels each say that using the drug with another GLP-1 receptor agonist is not recommended. Your prescriber sets the day you stop Saxenda and the day you start the new drug.
How much does Zepbound cost after switching from Saxenda?
LillyDirect lists the Zepbound KwikPen at $299 a month at the starting strength, rising with the dose to $449 at higher doses (read Nov 6, 2026). Your prescriber decides whether Zepbound fits.
Does Medicare's $50 GLP-1 Bridge cover Saxenda?
No. The CMS fact sheet for the Medicare GLP-1 Bridge names Foundayo, Wegovy and Zepbound KwikPen, at $50 a month for eligible Part D members.

New GLP-1 research drops every week.

Get the weekly digest: studies, safety alerts, coverage changes.

Ready to start?

Compare the recorded costs, sources and evidence gaps for 54 listed providers. Confirm current terms with the provider before enrolling.

Embody

from $49/mo, 12-month plan

Visit Embody